ESPNL

Summary

ESPNL (espin like, HGNC:27937) is a protein-coding gene on chromosome 2q37.3, encoding Espin-like protein (Q6ZVH7). Binds to but does not cross-link actin.

Predicted to enable actin filament binding activity. Predicted to be involved in actin filament bundle assembly and sensory perception of sound. Predicted to be located in stereocilium tip. Predicted to be active in cytoplasm.

Source: NCBI Gene 339768 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 267 total — 1 pathogenic
• MANE Select transcript: NM_194312

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:27937
Approved symbol	ESPNL
Name	espin like
Location	2q37.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ42568
Ensembl gene	ENSG00000144488
Ensembl biotype	protein_coding
OMIM	619974
Entrez	339768

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 4 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000343063, ENST00000409169, ENST00000409506, ENST00000423032, ENST00000477241

RefSeq mRNA: 2 — MANE Select: NM_194312 NM_001308370, NM_194312

CCDS: CCDS2525, CCDS77547

Canonical transcript exons

ENST00000343063 — 9 exons

Exon	Start	End
ENSE00001222582	238128707	238128904
ENSE00001222599	238125270	238125384
ENSE00001366247	238101941	238102131
ENSE00001367620	238107791	238107973
ENSE00001378370	238116903	238117034
ENSE00001379324	238130128	238133287
ENSE00001381095	238104656	238104842
ENSE00001421662	238100340	238100713
ENSE00003683324	238127622	238127734

Expression profiles

Bgee: expression breadth ubiquitous, 139 present calls, max score 70.72.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.1529 / max 56.7737, expressed in 44 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
26322	0.0613	16
26323	0.0458	12
26324	0.0299	18
26321	0.0158	7

Top tissues by expression

240 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
parotid gland	UBERON:0001831	70.72	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	69.72	gold quality
buccal mucosa cell	CL:0002336	68.88	gold quality
oocyte	CL:0000023	68.14	gold quality
mammary duct	UBERON:0001765	68.09	gold quality
right hemisphere of cerebellum	UBERON:0014890	67.82	gold quality
cerebellar vermis	UBERON:0004720	67.58	gold quality
cartilage tissue	UBERON:0002418	67.29	gold quality
cerebellar hemisphere	UBERON:0002245	67.14	gold quality
cerebellum	UBERON:0002037	66.99	gold quality
cerebellar cortex	UBERON:0002129	66.94	gold quality
mucosa of stomach	UBERON:0001199	66.64	gold quality
epithelium of nasopharynx	UBERON:0001951	66.61	gold quality
secondary oocyte	CL:0000655	66.57	gold quality
sperm	CL:0000019	66.25	gold quality
decidua	UBERON:0002450	66.24	silver quality
nasal cavity epithelium	UBERON:0005384	66.19	gold quality
vena cava	UBERON:0004087	65.93	gold quality
pharyngeal mucosa	UBERON:0000355	65.68	gold quality
right ovary	UBERON:0002118	64.82	gold quality
inferior vagus X ganglion	UBERON:0005363	64.73	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	64.69	gold quality
nipple	UBERON:0002030	64.63	gold quality
synovial joint	UBERON:0002217	64.55	gold quality
saphenous vein	UBERON:0007318	64.47	gold quality
right lobe of liver	UBERON:0001114	64.44	gold quality
amniotic fluid	UBERON:0000173	64.43	gold quality
subthalamic nucleus	UBERON:0001906	64.41	gold quality
body of tongue	UBERON:0011876	64.35	gold quality
pericardium	UBERON:0002407	64.32	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.10

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

26 targeting ESPNL, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-6124	99.87	69.78	3551
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-6752-3P	99.72	66.71	1587
HSA-MIR-1827	99.63	68.57	3265
HSA-MIR-1915-3P	99.58	66.79	1988
HSA-MIR-4667-3P	99.26	65.45	1608
HSA-MIR-4291	99.20	68.88	2969
HSA-MIR-4279	99.19	66.70	2437
HSA-MIR-4426	99.17	66.74	1949
HSA-MIR-3619-5P	99.00	68.87	2308
HSA-MIR-214-3P	98.71	68.12	2128
HSA-MIR-761	98.71	68.07	2051
HSA-MIR-1227-5P	98.65	65.32	1549
HSA-MIR-4290	98.51	65.17	907
HSA-MIR-4726-3P	98.49	63.89	1385
HSA-MIR-6742-3P	97.95	64.50	1490
HSA-MIR-296-5P	97.61	64.02	851
HSA-MIR-6872-3P	97.08	66.99	750
HSA-MIR-3622A-3P	97.06	66.43	1000
HSA-MIR-3622B-3P	96.82	66.36	988
HSA-MIR-582-3P	96.69	67.38	1019
HSA-MIR-7973	96.48	65.54	502

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	espnla	ENSDARG00000078211
danio_rerio	espnlb	ENSDARG00000093112
mus_musculus	Espnl	ENSMUSG00000049515
rattus_norvegicus	Espnl	ENSRNOG00000024717
drosophila_melanogaster	f	FBGN0262111
caenorhabditis_elegans		WBGENE00012319

Paralogs (1): ESPN (ENSG00000187017)

Protein

Protein identifiers

Espin-like protein — Q6ZVH7 (reviewed: Q6ZVH7)

All UniProt accessions (2): Q6ZVH7, C9J6L8

UniProt curated annotations — full annotation on UniProt →

Function. Binds to but does not cross-link actin. Required for the formation and maintenance of inner ear hair cell stereocilia and staircase formation. Essential for normal hearing.

Subunit / interactions. Interacts with MYO3A (via C-terminus). Interacts with MYO3B (via C-terminus).

Subcellular location. Cell projection. Stereocilium.

Isoforms (3)

UniProt ID	Names	Canonical?
Q6ZVH7-1	1	yes
Q6ZVH7-2	2
Q6ZVH7-3	3

RefSeq proteins (2): NP_001295299, NP_919288* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002110	Ankyrin_rpt	Repeat
IPR036770	Ankyrin_rpt-contain_sf	Homologous_superfamily
IPR052420	Espin/Espin-like	Family

Pfam: PF12796, PF13637

UniProt features (28 total): repeat 9, region of interest 5, sequence variant 5, sequence conflict 3, compositionally biased region 2, splice variant 2, chain 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6ZVH7-F1	65.57	0.32

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-9662360	Sensory processing of sound by inner hair cells of the cochlea
R-HSA-9662361	Sensory processing of sound by outer hair cells of the cochlea

MSigDB gene sets: 39 (showing top): GOBP_ACTIN_FILAMENT_BUNDLE_ORGANIZATION, GOBP_SENSORY_PERCEPTION_OF_MECHANICAL_STIMULUS, GOBP_ACTIN_FILAMENT_ORGANIZATION, RYTTCCTG_ETS2_B, GOBP_SENSORY_PERCEPTION, GOMF_ACTIN_BINDING, GOCC_NEURON_PROJECTION, GOCC_STEREOCILIUM_BUNDLE, GOCC_CLUSTER_OF_ACTIN_BASED_CELL_PROJECTIONS, GOCC_ACTIN_BASED_CELL_PROJECTION, GOMF_CYTOSKELETAL_PROTEIN_BINDING, DODD_NASOPHARYNGEAL_CARCINOMA_DN, GOBP_SUPRAMOLECULAR_FIBER_ORGANIZATION, GOCC_STEREOCILIUM_TIP, GOMF_PROTEIN_CONTAINING_COMPLEX_BINDING

GO Biological Process (2): sensory perception of sound (GO:0007605), actin filament bundle assembly (GO:0051017)

GO Molecular Function (3): actin filament binding (GO:0051015), actin binding (GO:0003779), protein binding (GO:0005515)

GO Cellular Component (4): cytoplasm (GO:0005737), stereocilium tip (GO:0032426), stereocilium (GO:0032420), cell projection (GO:0042995)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Sensory processing of sound	2

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
sensory perception of mechanical stimulus	1
cellular component assembly	1
actin filament bundle organization	1
actin binding	1
protein-containing complex binding	1
cytoskeletal protein binding	1
binding	1
intracellular anatomical structure	1
stereocilium	1
stereocilium bundle	1
neuron projection	1
actin-based cell projection	1

Protein interactions and networks

STRING

1099 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ESPNL	MYO3B	Q8WXR4	708
ESPNL	MYO3A	Q8NEV4	675
ESPNL	EPS8L2	Q9H6S3	580
ESPNL	LRRC30	A6NM36	573
ESPNL	MATCAP1	Q68EN5	560
ESPNL	WHRN	Q9P202	533
ESPNL	KLHL18	O94889	531
ESPNL	MORN4	Q8NDC4	523
ESPNL	MYO15A	Q9UKN7	512
ESPNL	GRXCR1	A8MXD5	501
ESPNL	PLS1	Q14651	487
ESPNL	TMEM266	Q2M3C6	475
ESPNL	EPS8	Q12929	450
ESPNL	FSCN2	O14926	445
ESPNL	EFHB	Q8N7U6	435

IntAct

11 interactions, top by confidence:

A	B	Type	Score
SERTAD2	ESPNL	psi-mi:“MI:0915”(physical association)	0.560
ESPNL	PFDN5	psi-mi:“MI:0915”(physical association)	0.560
LDLRAP1	ESPNL	psi-mi:“MI:0915”(physical association)	0.560
KLHL22	TRAV18	psi-mi:“MI:0914”(association)	0.350
ESPNL	SERTAD2	psi-mi:“MI:0915”(physical association)	0.000
ESPNL	PFDN5	psi-mi:“MI:0915”(physical association)	0.000
LDLRAP1	ESPNL	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (6): ESPNL (Two-hybrid), LDLRAP1 (Two-hybrid), SERTAD2 (Two-hybrid), ESPNL (Affinity Capture-MS), ESPNL (Proximity Label-MS), ESPNL (Proximity Label-MS)

ESM2 similar proteins: A0A0U1RQ45, A0A0U1RQS6, A0A2R8YCJ5, A2A699, A2AEV7, A6NGB7, A6NJG2, A6NKF7, A6NKL6, A6NL88, A8MVW0, A9JSM3, B2RU40, B8ZZ34, C9JH25, D4A9R4, J3QNX5, P0CG09, P98077, Q0VD38, Q14761, Q17QH7, Q29RK8, Q2KJ18, Q2M3V2, Q3SX20, Q5BJT1, Q5HZJ5, Q5RKR3, Q5T442, Q64697, Q69YZ2, Q6PB97, Q6PCT2, Q6UXK2, Q6ZMQ8, Q6ZVH7, Q6ZW31, Q80XF7, Q8BLS7

Diamond homologs: A0A0R4IQZ2, A2AS55, A4II29, B4E2M5, C7B178, G0LXV8, L7X8P2, L7XCU0, L7XDS4, P0C0T2, P0C550, P0DJE3, P19838, P23631, P39010, Q04749, Q04861, Q0JKV1, Q10728, Q18297, Q28C34, Q337A0, Q38998, Q3SX00, Q3UMT1, Q3UX43, Q499M5, Q4JHE0, Q5H9F3, Q5R8C8, Q5U5A6, Q63369, Q68DC2, Q6FJ70, Q6GQX6, Q6NRD0, Q6NY19, Q6P6B7, Q6P9J5, Q6ZVH7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

267 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	244
Likely benign	13
Benign	2

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
997810	Single allele	Pathogenic

SpliceAI

1938 predictions. Top by Δscore:

Variant	Effect	Δscore
2:238104654:A:AG	acceptor_gain	1.0000
2:238104655:G:GG	acceptor_gain	1.0000
2:238104655:GCA:G	acceptor_gain	1.0000
2:238104838:GGCTG:G	donor_gain	1.0000
2:238104839:GCTG:G	donor_gain	1.0000
2:238104839:GCTGG:G	donor_gain	1.0000
2:238104843:G:GG	donor_gain	1.0000
2:238104844:T:A	donor_loss	1.0000
2:238116901:A:AG	acceptor_gain	1.0000
2:238116902:G:GG	acceptor_gain	1.0000
2:238117031:GCCG:G	donor_gain	1.0000
2:238117032:CCGG:C	donor_loss	1.0000
2:238117035:G:C	donor_loss	1.0000
2:238117035:G:GG	donor_gain	1.0000
2:238117036:T:A	donor_loss	1.0000
2:238125382:GCC:G	donor_gain	1.0000
2:238125385:G:GG	donor_gain	1.0000
2:238128901:CCAG:C	donor_loss	1.0000
2:238128903:AG:A	donor_loss	1.0000
2:238128904:GGTAG:G	donor_loss	1.0000
2:238128905:G:GA	donor_loss	1.0000
2:238100711:CAGG:C	donor_loss	0.9900
2:238100712:AGGT:A	donor_loss	0.9900
2:238100713:GG:G	donor_loss	0.9900
2:238100714:G:A	donor_loss	0.9900
2:238102127:GGCAG:G	donor_gain	0.9900
2:238102128:GCAG:G	donor_gain	0.9900
2:238102128:GCAGG:G	donor_gain	0.9900
2:238102130:AGG:A	donor_loss	0.9900
2:238102131:GGTA:G	donor_loss	0.9900

AlphaMissense

6426 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:238128836:T:A	W449R	0.996
2:238128836:T:C	W449R	0.996
2:238107953:G:C	A279P	0.993
2:238128838:G:C	W449C	0.993
2:238128838:G:T	W449C	0.993
2:238107858:C:A	A247D	0.991
2:238107939:C:A	P274H	0.991
2:238107942:T:A	L275H	0.989
2:238107855:C:A	A246E	0.987
2:238107939:C:G	P274R	0.987
2:238107950:G:C	A278P	0.987
2:238116976:T:C	L310P	0.987
2:238104805:C:A	A212D	0.986
2:238107851:T:C	F245L	0.986
2:238107853:T:A	F245L	0.986
2:238107853:T:G	F245L	0.986
2:238131691:T:A	W993R	0.986
2:238131691:T:C	W993R	0.986
2:238107891:T:C	L258P	0.985
2:238104808:C:A	A213D	0.984
2:238107857:G:C	A247P	0.984
2:238116978:G:C	A311P	0.984
2:238131396:G:C	W894C	0.984
2:238131396:G:T	W894C	0.984
2:238131412:T:C	F900L	0.984
2:238131414:C:A	F900L	0.984
2:238131414:C:G	F900L	0.984
2:238104705:T:C	C179R	0.983
2:238104837:T:A	W223R	0.983
2:238104837:T:C	W223R	0.983

dbSNP variants (sampled 300 via entrez): RS1000093965 (2:238114893 C>T), RS1000143784 (2:238109979 A>G), RS1000145006 (2:238104718 A>G), RS1000259275 (2:238121211 A>G), RS1000263045 (2:238116214 A>C), RS1000305408 (2:238126907 G>A), RS1000364944 (2:238125959 T>C), RS1000456137 (2:238100913 T>A,C), RS1000572532 (2:238126796 GTGTA>G), RS1000612764 (2:238101114 G>A,C), RS1000727762 (2:238120091 G>A), RS1000805144 (2:238130978 C>A,T), RS1000832228 (2:238124538 T>A), RS1000913488 (2:238111391 T>G), RS1000992560 (2:238120375 C>A)

Disease associations

OMIM: gene MIM:619974 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): intellectual disability (MONDO:0001071)

Orphanet (1): NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

16 total (human), top 16 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Aflatoxin B1	increases methylation, increases expression	3
aristolochic acid I	increases expression	1
bisphenol A	affects methylation	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
aflatoxin B2	increases methylation	1
2-palmitoylglycerol	increases expression	1
(+)-JQ1 compound	decreases expression	1
2,3,5-trichloro-6-phenyl-(1,4)benzoquinone	increases expression	1
Resveratrol	decreases expression, affects cotreatment	1
Temozolomide	decreases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Rotenone	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Valproic Acid	increases methylation	1
Cadmium Chloride	decreases expression	1
Okadaic Acid	increases expression	1

Clinical trials (associated diseases)

197 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT03479476	PHASE2/PHASE3	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome
NCT02616796	PHASE1/PHASE2	COMPLETED	Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome
NCT06860672	EARLY_PHASE1	RECRUITING	Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation
NCT00597948	Not specified	COMPLETED	Healthy Lifestyles for People With Intellectual Disabilities
NCT01087320	Not specified	RECRUITING	Genome Medical Sequencing for Gene Discovery
NCT01652963	Not specified	UNKNOWN	Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills
NCT01695395	Not specified	COMPLETED	Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder
NCT01867554	Not specified	COMPLETED	Research and Characterization of New Genes Involved in Intellectual Disability
NCT01915381	Not specified	COMPLETED	Improving Adherence Healthy Lifestyle With a Smartphone Application Based on Adults With Intellectual Disabilities
NCT01988623	Not specified	COMPLETED	Pivotal Response Treatment for Individuals With Intellectual Disabilities
NCT02099773	Not specified	COMPLETED	Support Staff-client Interactions With Augmentative and Alternative Communication
NCT02136849	Not specified	COMPLETED	Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic
NCT02225041	Not specified	COMPLETED	Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood
NCT02414438	Not specified	COMPLETED	Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study
NCT02451761	Not specified	COMPLETED	Apparently Balanced Chromosomal Translocation/ Next-generation Sequencing/ Intellectual Disability
NCT02461420	Not specified	ACTIVE_NOT_RECRUITING	Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome
NCT02461459	Not specified	ACTIVE_NOT_RECRUITING	Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
NCT02486081	Not specified	COMPLETED	Development and Application-Smart Football for Movement Evaluation and Training in the Special Education Population
NCT02504502	Not specified	COMPLETED	Enhancing Genomic Laboratory Reports to Enhance Communication and Empower Patients
NCT02513277	Not specified	COMPLETED	Diabetes Screening & Prevention for People With Learning (Intellectual) Disabilities:STOP Diabetes Study
NCT02561754	Not specified	COMPLETED	Weight Management for Adolescents With IDD
NCT02591446	Not specified	COMPLETED	Transcranial Magnetic Stimulation Studies in Autism Spectrum Disorders
NCT02714868	Not specified	COMPLETED	Evaluation of Project TEAM (Teens Making Environmental and Activity Modifications)
NCT02721394	Not specified	UNKNOWN	FCT With Young Children With ID in the UK: A Feasibility Project V.1
NCT02746614	Not specified	COMPLETED	Psychomotor Therapy Effects in Adaptive Behavior and Motor Proficiency in Intellectual Disability
NCT02836405	Not specified	COMPLETED	TMS for the Investigation of Brain Plasticity in Autism Spectrum Disorders